The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

GLP-1 is a hormone naturally produced by the body that plays a key role in appetite regulation, blood sugar control, and ...

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

You also have another product in your pipeline called Rejuva, which is a one-time gene therapy platform. Can you tell me about that and how it works? Yeah, we’re developing a smart GLP-1 gene therapy.

The acronym GLP-1 has become an increasingly popular term in the health arena, especially in the context of weight loss.

Eli Lilly completed a phase 3 trial for its weight loss drug, orforglipron, which showed promising results in evaluating its safety and efficacy for adults with Type 2 diabetes and inadequate glycemic ...

Source Reference: Sundaram V, et al "TRANSFORM-AF: targeting metabolic therapy with GLP-1 receptor agonism for secondary prevention in atrial fibrillation" HRS 2025.

I can't think of another time in history when as many patients were served by a particular compounded therapy,” says Scott ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Researchers have identified GLP-1 receptor agonists, a class of drugs currently used to treat type-2 diabetes and obesity, as ...